Table 3.

Multivariable hazard ratios (HR) and 95 % confidence intervals (CIs) for risk of endometrial cancer by tertiles of parent estrogens and estrogen metabolite pathways

Estrogen/EM	Cases (n = 66)	Subcohort (n = 346)	HR (95 % CI)a	HR (95 % CI)b	HR (95 % CI)c
Total parents (E1 + E2)
T1	15	114	1.00	1.00
T2	22	114	1.29 (0.63, 2.64)	1.14 (0.54, 2.39)	n/a
T3	29	118	1.69 (0.83, 3.45)	1.37 (0.64, 2.93)	n/a
p trend			0.15	0.41	n/a
Estrone (E1)
T1	16	115	1.00	1.00	1.00
T2	19	113	1.06 (0.52, 2.19)	0.93 (0.43, 1.98)	0.86 (0.41, 1.83)
T3	31	118	1.75 (0.87, 3.52)	1.44 (0.69, 3.03)	0.86 (0.38, 1.95)
p trend			0.10	0.29	0.73
Estradiol (E2)
T1	7	114	1.00	1.00
T2	21	115	2.57 (1.06, 6.20)	2.42 (0.97, 6.00)	n/a
T3	38	117	4.38 (1.82, 10.5)	4.09 (1.70, 9.85)	n/a
p trend			0.0006	0.003	n/a
2-Pathway
T1	11	115	1.00	1.00	1.00
T2	24	113	1.86 (0.87, 4.01)	1.77 (0.77, 4.07)	1.59 (0.72, 3.48)
T3	31	118	2.21 (1.02, 4.79)	1.92 (0.84, 4.37)	1.17 (0.49, 2.79)
p trend			0.05	0.16	0.87
4-Pathway
T1	11	115	1.00	1.00	1.00
T2	23	113	1.78 (0.81, 3.90)	1.68 (0.72, 3.91)	1.54 (0.69, 3.46)
T3	32	118	2.29 (1.08, 4.89)	1.95 (0.87, 4.38)	1.36 (0.60, 3.06)
p trend			0.03	0.11	0.56
16-Pathway
T1	12	114	1.00	1.00	1.00
T2	22	115	1.49 (0.70, 3.17)	1.33 (0.61, 2.93)	1.25 (0.58, 2.71)
T3	32	117	2.24 (1.07, 4.68)	1.88 (0.86, 4.12)	1.21 (0.53, 2.74)
p trend			0.03	0.11	0.69

The following tertile categories (T1, T2, T3 pmol/L) are based on the distribution of each estrogen or estrogen metabolite among the subcohort: total parents (<236.51, 236.51–427.12, >427.12), estrone (<200.47, 200.47–367.82, >367.82), estradiol (<27.67, 27.67–51.28, >51.28), 2-pathway (<99.77, 99.77–140.72, >140.72), 4-pathway (<14.61, 14.61–19.55, >19.55), 16-pathway (<234.36, 234.36–377.21, >377.21)

^aAdjusted for clinic and trial participation status

^bAdjusted for clinic, trial participation status, and body mass index

^cAdjusted for clinic, trial participation status, and estradiol